Marijuana Penny Stocks Recap: Organigram Stock Might Be Volatile

marijuana penny stocks

The onset of the coronavirus pandemic may have come as a death blow to most sectors, but with regards to the cannabis space, it should be noted that most marijuana penny stocks were already declining significantly over the past year. The sector was going through difficulties even before the latest crisis hit, and during the past 12 months, many of these stocks have recorded declines to the tune of 50% or more.

One of the most important things to keep in mind about penny stocks is the fact that these stocks offer an opportunity to generate significant gains from a relatively low investment. Despite the legalization of marijuana in Canada, many companies in the country have struggled to post profits due to a range of issues. Oversupply, slow rollout of stores and the continued presence of the illegal market have been cited as some of the factors.

With all that's going on, here are three marijuana penny stocks investors may want to keep an eye on:

Marijuana Penny Stocks Recap: Organigram Holdings (TSX:OGI) (NASDAQ:OGI)

marijuana penny stocks

Organigram Holdings is regarded as one of the more promising companies in the sector. However, investors were left disappointed with the company’s fiscal second-quarter results, which were released last week. Organigram stock has dropped by 40% in 2020 so far.

One of the more worrying factors from the second-quarter results was the fact that Organigram’s revenue slumped to C$23.2 million from C$26.9 million in the prior-year period. Three of its clients each make up around 10% of the company's revenue, but with cash drying up for many entities in the sector, this has become a red flag for investors.

The company ended the second quarter with C$41.1 million, but it emerged that in six months, Organigram had burned through C$25 million on operating costs. The decline in demand is inevitable due to the looming economic troubles, and that could put more pressure on Organigram to reduce costs.

>> 3 Top Cannabis Stocks to Play: Aphria Stock Leads

The company’s weak cash position makes it vulnerable to such upheavals. While Organigram stock may have been one of the more promising marijuana penny stocks in the market, it could experience increased volatility in the coming months.

Marijuana Penny Stocks Recap: Planet 13 Holdings (CSE:PLTH) (OTCQB:PLNHF)

Nevada-based Planet 13 Holdings has emerged as one of the more interesting marijuana companies in recent times. The launch of its SuperStore in Las Vegas has been one of the key factors behind its growth, and last week, and it announced its Q4 and full-year earnings for 2019.

The company’s revenue in the fourth quarter rose to $16.5 million, which reflects a year-on-year jump of 99.8%. Planet 13 generated EBITDA earnings of $2.5 million for the quarter.

The company also provided a glimpse into the fiscal first quarter, revealing that it expects revenue to be around $16.6 million. Considering the fact that the coronavirus pandemic has affected the sector significantly, the upcoming quarter may offer a strong performance from the company.

However, investors also need to keep in mind that the coronavirus pandemic has now resulted in the closure of its SuperStore in Las Vegas, and that could have a major impact on its business in the coming months.

Marijuana Penny Stocks Recap: MediPharm Labs (TSX:LABS) (OTCQX:MEDIF)

marijuana penny stocks

One of the marijuana penny stocks that investors could keep an eye on over the coming days is MediPharm Labs. The extraction service provider is apparently all set to post a profit of C$0.12 million in the 2021 fiscal year.

The most important factor behind MediPharm’s growth is that the contracts it has signed range from 12 to 18 months, which will provide the company with a steady cash flow during these uncertain times. While the company’s processing capabilities are around 50% that of its rival Valens (TSX:VLNS), this could also be a major reason why MediPharm could control costs far more effectively.

However, the current difficulties of one of its clients, HEXO (TSX:HEXO) (NYSE:HEXO), have proven to be a problem for MediPharm. HEXO Corp had been sued by MediPharm for breaching its contract, and in the long-term, it could lose HEXO as one of its clients. There may be difficulties in the coming months, but it seems that MediPharm stock is on track to remain profitable.

>> Read More Penny Stock News

Featured image: DepositPhotos © Piter2121

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.